into the pharmacodynamic profile of an antiplatelet agent. Coated-platelets are a subpopulation of activated platelets generated on dual-agonist stimulation with collagen plus thrombin. 1 These cells are characterized by the retention of several α-granule proteins on their surface, exposure of phosphatidylserine, and support for a robust prothrombinase activity. 1 In normal subjects, 30% to 35% of platelets become coatedplatelets on activation with collagen and thrombin. 1 Adenosine-5′-diphosphate (ADP) is an important, but relatively weak, platelet agonist that can independently induce aggregation or act to amplify activation of platelets by other agonists. 2 ADP has 2 receptors on the platelet surface, P2Y 1 and P2Y 12 , 3 and inhibition of either receptor has been shown to reduce ADP-induced platelet aggregation. 3 Cangrelor is a selective inhibitor of the platelet P2Y 12 receptor that has been shown to achieve high degrees of inhibition of ADP-induced platelet aggregation. 4
Introduction
Pharmacodynamic studies of antiplatelet drugs are typically performed in vitro with single agonist activation of platelets. However, in vivo multiple agonists can potentially activate platelets at a site of vascular injury; thus, investigations using multiple agonists may more closely mimic the in vivo setting and thereby have the potential to offer additional insight P2Y 12 inhibitors were introduced clinically as effective inhibitors of adenosine-5′-diphosphate (ADP) mediated platelet activation and aggregation. This class of pharmacological agents has enjoyed considerable success. Cangrelor is a recently developed P2Y 12 inhibitor that has the advantage of being an active drug not requiring metabolic conversion, although it is not orally available. Coated-platelets are a subclass of activated platelets generated on dual agonist activation with collagen plus thrombin; the primary hallmark of coated-platelets is their ability to support prothrombinase activity. Interestingly, we recently observed that the relatively weak agonist ADP potentiates the production of coated-platelets by the very strong agonists collagen plus thrombin, a previously unknown role for ADP. The authors sought in this study to determine if P2Y 12 inhibitors, such as cangrelor, were capable of attenuating this augmentation of coated-platelet generation. Cangrelor, at physiologically relevant concentrations, was able to eliminate the ADP-dependent increase in coated-platelet production with an IC 50 of 1.4 nM. Cangrelor, however, had no effect on thrombin-dependent platelet activation as measured by P-selectin expression. Although this in vitro study does not address the question of whether the effectiveness of cangrelor in vivo is partially due to an attenuation of coated-platelet production in addition to its documented antiaggregatory effects, it does reveal an unexpected action of cangrelor. Additional studies will be required to determine if all P2Y 12 inhibitors are equally effective in attenuating coated-platelet production. Clinically, cangrelor is being evaluated in patients undergoing percutaneous coronary intervention (PCI), including individuals with acute coronary syndromes.
Keywords: platelet; cangrelor; antiplatelet
Preliminary studies in vitro have shown that the weak agonist ADP can augment the effect of thrombin plus collagen and increase the percentage of platelets that are converted to coated-platelets (N. Norgard, manuscript in preparation). This observation is supported by a recent report that ADP potentiates, via the P2Y 12 receptor, microparticle formation, 5 a key index of coated-platelet formation. 6 The objective of this study was to evaluate the effect of cangrelor, a specific P2Y 12 inhibitor, on coated-platelet production and to provide possible insight into the antithrombotic mechanisms of a selective P2Y 12 receptor inhibitor that is being investigated for clinical use.
Materials and Methods

Materials
Cangrelor was kindly provided by the Medicines Company (Parsippany, NJ). Convulxin was purified as previously described. 7 Bovine thrombin and gly-pro-arg-pro-amide were obtained from Sigma Chemicals (St Louis, MO). Phycoerythrin-streptavidin was from Molecular Probes (Eugene, OR). Biotinfibrinogen and FITC-abciximab were prepared as previously described. 8 All other reagents were obtained from sources as detailed. 7
Coated-Platelet Assay
Normal blood donors were recruited and consented in accordance with local institutional review board requirements. Blood was drawn into one tenth volume of acid-citrate-dextrose, and platelet-rich plasma was prepared as previously described. 7 Coated-platelets were assayed 9 with 1 μL of platelet-rich plasma in 100 μL (total volume) with the following final concentrations of ingredients: 2 mM CaCl 2 , 1 mM MgCl 2 , 0.2 mM gly-pro-arg-pro, 1 μg/mL biotin-fibrinogen, 500 ng/mL convulxin, 7 0.5 U/mL bovine thrombin, 150 mM NaCl, and 10 mM HEPES, pH 7.5. After 5 minutes at 37°C, 0.8 μg of phycoerythrin-streptavidin and 0.5 μg of FITC-abciximab were added. After 10 minutes of incubation at 37°C, 200 μL of 1.5% (w/v) formalin was added to quench any further reaction. The generation of coated-platelets was quantitated by flow cytometry as previously described. 8, 10 Results Activation of platelets with convulxin plus thrombin generates a subpopulation of coated-platelets, 11 as shown in Figure 1B ; bound biotin-fibrinogen is used as the marker of coated-platelets in this particular assay. 10 Addition of a third agonist, 6 μM ADP, results in an increase in the percentage of cells converted into coated-platelets ( Figures 1C and D) , and inclusion of 2 μM cangrelor totally inhibits the ADP-induced increase in coated-platelets ( Figure  1E ). Figure 2 summarizes results with 5 donors. A total of 6 μM ADP increased coated-platelet levels from 35.9% ± 8.3% (mean ± 1 SD, n = 5) to 59.1% ± 8.4% (n = 5; P < .001); however, both 0.1 and 2 μM cangrelor totally inhibited the ADP-induced potentiation of coated-platelet production (27.4 ± 7.9; n = 5; P = .0003; Figure 2B ). In addition, both 0.1 and 2 μM cangrelor also had a small but significant effect on coated-platelet production by just convulxin plus thrombin (27.4 ± 6.2; n = 5; P = .004; Figure 2A ). A dose-response curve for cangrelor's inhibition of the ADP-induced potentiation of coated-platelet formation is shown in Figure 3 , indicating an IC 50 of approximately 1.4 nM.
Cangrelor was examined for other effects on platelet activation. Figure 4A shows a thrombin dose-response curve for P-selectin expression, with and without 1 μM cangrelor. Cangrelor had no effect on thrombin-mediated activation with this particular endpoint of α-granule secretion. However, when ADP-induced activation of glycoprotein IIb/IIIa was monitored by the binding of FITC-PAC-1, 12 cangrelor had the expected effect of inhibiting this particular assay ( Figure 4B ). The IC 50 for cangrelor inhibition of ADP-mediated activation of glycoprotein IIb/IIIa was approximately 2.6 nM.
Discussion
Coated-platelets represent a subpopulation of dual-agonist-activated platelets that retain several α-granule proteins on their surface, including fibrinogen, factor V, von Willebrand factor, fibronectin, and α 2 -antiplasmin. 1 Coated-platelets are also a potent source of prothrombinase activity. 7 Dual-agonist activation for the formation of coated-platelets can be achieved with thrombin plus collagen or thrombin plus convulxin, a snake venom agonist of glycoprotein VI. 14 The average percentage of coatedplatelets formed by normal controls is 30% to 35%. 1 One aspect of coated-platelet formation that has not been widely appreciated is that a triple-agonist mixture of convulxin, thrombin, and ADP produces even larger numbers of coated-platelets (N. Norgard, manuscript in preparation). This observation is particularly surprising in that ADP, a relatively weak agonist, would be expected to be a minor contributor in the context of high concentrations of the 2 powerful agonists, thrombin and convulxin, that are used in this assay. However, as shown in Figure 2 , inclusion of 6 μM ADP increased the percentage of coated platelets produced by 64% (relative) or 23% (absolute). Also shown in Figure 2 is the ability of cangrelor, a P2Y 12 inhibitor, to prevent this ADP-induced increase. Interestingly, cangrelor also has a significant, but smaller, impact on coated-platelet formation with just convulxin plus thrombin, producing a 22% (relative) decrease (8.5%, absolute), suggesting a role for endogenous ADP in coated-platelet formation.
Cangrelor is being developed as a potential replacement for the commonly used P2Y 12 inhibitor, clopidogrel, in periprocedural antiplatelet therapy of PCI. Multiple studies have demonstrated the clinical effectiveness of P2Y 12 receptor inhibition with clopidogrel in the setting of PCI. Cangrelor, an ATP analog, achieves rapid, reversible inhibition of platelet aggregation via competitive binding to the P2Y 12 receptor. In comparison with clopidogrel, cangrelor has been shown to offer more rapid and more complete inhibition of platelet reactivity as measured by ADP-induced platelet aggregation. 4 These data lead to speculation that cangrelor may have additional antithrombotic effects in vivo beyond simple inhibition of ADP-induced aggregation, specifically, an ability to attenuate coatedplatelet formation in vivo. Such an inhibition may have important consequences in a clinical setting although analysis of this question is complicated by 2 points: first, the extent to which ADP affects coated-platelets in vivo is unknown, and second, the consequences of coated-platelet inhibition in vivo are still speculative. It is clear that a near total deficiency of coated-platelets results in a bleeding diathesis. 8 This was documented by Brooks et al, 15 who described German Shepherd dogs with a bleeding disorder similar to Scott syndrome in humans and recently demonstrated that these dogs lack the ability to produce coated-platelets. 8 still not clear that a partial attenuation of coatedplatelet production would have a significant impact. Although clinical studies indicate that elevated coated-platelet production is observed in patients with cortical strokes, 16 definitive demonstration of a deleterious effect of increased coated-platelet levels remains to be seen.
In conclusion, these data demonstrate that cangrelor has potential effects on coagulation beyond simple inhibition of ADP-induced aggregation. Whether all P2Y 12 inhibitors will have similar profiles will require further investigation. Cangrelor effect on other platelet parameters. A, Graded doses of thrombin in the presence or absence of 2 μM cangrelor were used to activate platelets; surface expression of Pselectin was used as a marker of platelet activation. 13 Cangrelor had no demonstrable effect. B, 5 μM ADP was used to activate platelets in the presence of graded doses of cangrelor; binding of FITC-PAC-1 to activated glycoprotein IIb/IIIa was used as the marker of platelet activation. 12 As expected, cangrelor inhibited ADP-mediated activation of glycoprotein IIb/IIIa.
